Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flucytosine SCHEMBL3868994 | 0.73 | RXFP1 (0.36) | RXFP1 | |
| SCHEMBL8405047 | 0.73 | LMNA (0.50) | KDM4ERAB9AMAPTCYP3A4TSHR | |
| SCHEMBL3585568 | 0.71 | — | — | |
| SCHEMBL597893 | 0.70 | TDP1 (0.50) | MAPTCYP3A4TSHRLMNACYP1A2 | |
| SCHEMBL5143009 | 0.70 | — | — | |
| SCHEMBL1231792 | 0.67 | ATAD2 (0.37) | CYP1A2 | |
| SCHEMBL22008 | 0.67 | — | — | |
| Flucytosine SCHEMBL8160959 | 0.67 | ALDH1A1 (0.37) | MAPTTSHRLMNAALDH1A1 | |
| SCHEMBL1765946 | 0.67 | — | — | |
| SCHEMBL30609151 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-27 | — | — | US | claimed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | claimed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | claimed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | claimed |
| CN-112105627-A | Non-natural base pair compositions and methods of use | 斯克利普斯研究所 | 2020-12-18 | — | — | CN | claimed |
| EP-3732187-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | The Scripps Research Institute (US) | 2020-11-04 | — | — | EP | claimed |
| US-20200318122-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2020-10-08 | — | — | US | claimed |
| WO-2016115168-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2016-07-21 | — | — | WO | claimed |
| WO-2015157555-A2 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-15 | — | — | WO | claimed |
| US-8133669-B2 | Chemically modified nucleoside 5′-triphosphates for thermally initiated amplification of nucleic acid | TRILINK BIOTECHNOLOGIES (US) | 2012-03-13 | — | — | US | claimed |
| EP-2294076-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink BioTechnologies (US) | 2011-03-16 | — | — | EP | claimed |
| US-20100003724-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink Bio Technologies | 2010-01-07 | — | — | US | claimed |
| WO-2009151921-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090149411-A1 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF | DYNAVAX TECHNOLOGIES CORPORATION | 2009-06-11 | — | — | US | claimed |
| US-20040092468-A1 | Immunostimulatory oligonucleotides with modified bases and methods of use thereof | SCHWARTZ DAVID (US) | 2004-05-13 | — | — | US | claimed |
| EP-1121373-A2 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF | Dynavax Technologies Corporation (US) | 2001-08-08 | — | — | EP | claimed |
| WO-1999062923-A2 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 1999-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | KDM4E 4290/4885RAB9A 2218/4885MAPT 852/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | KDM4E 4046/4885RAB9A 2910/4885MAPT 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.